Pretomanid Approval Status
FDA Approved: No
Generic name: pretomanid
Company: TB Alliance
Treatment for: Tuberculosis, Resistant
Pretomanid is a nitroimidazooxazine in development for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of extensively drug-resistant (XDR) tuberculosis (TB), treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.
Development Status and FDA Approval Process for pretomanid
|Mar 8, 2019||TB Medicine Pretomanid Enters Regulatory Review Process in the United States|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.